Search results
Hyperkalaemia in Heart Failure
Author(s):
Umar Ismail
,
Kiran Sidhu
,
Shelley Zieroth
Added:
2 years ago
Article
Author(s):
Mitja Lainscak
Added:
3 years ago
The renin–angiotensin–aldosterone system (RAAS) is an essential regulatory component of cardiovascular homeostasis that exerts its actions through hormones, angiotensin II and aldosterone, which regulate vascular tone and blood pressure by causing vasoconstriction and renal sodium and water retention.1 Abnormalities in cardiac function in heart failure (HF) activate the RAAS and sympathetic…
View more
Author(s):
Giuseppe Rosano
,
Ilaria Spoletini
,
Cristiana Vitale
,
et al
Added:
3 years ago
Heart failure (HF) affects 1–2% of the population in developed countries and absorbs a significant amount of human and economic resources.1,2 HF is a complex syndrome characterised by a spectrum of symptoms and phenotypes: HF with preserved ejection fraction, HF with mid-range ejection fraction and HF with reduced ejection fraction (HFrEF).3 Differentiating patients according to left ventricular…
View more
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article
Author(s):
Jeffrey Testani
Added:
4 years ago
Dr Jeffrey Testani (Yale School of Medicine, New Haven, Connecticut, US) discusses the Zero Sodium Peritoneal Dialysate Protocol Pilot Study –First in human experience with direct sodium removal using a zero sodium peritoneal solution: A new candidate therapy for volume overload.
Filmed on site at HFA 2019 by Radcliffe Cardiology.
Videographer: Mike Knight
Interviewer: Liam O'Neill
View more
Author(s):
Justin Ezekowitz
,
Harriette Van Spall
Added:
1 year ago
In this in-depth conversational interview, Late-breaker host Dr Harriette Van Spall(McMaster University, CA) meets PI, Dr Justin A. Ezekowitz (University of Alberta, CA) to discuss the SODIUM-HF trial (CT02012179). The aim of the trial was to evaluate the effects of a low-sodium diet, compared to usual care in patients with heart failure.
Presented first at ACC.22, the trial showed that reducing…
View more
Author(s):
Muhammad Shahzeb Khan
,
Javed Butler
Added:
4 years ago
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events…
View more
Author(s):
Thomas A Zelniker
,
Eugene Braunwald
Added:
3 years ago
With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the…
View more
Author(s):
Giuseppe Rosano
,
David Quek
,
Felipe Martínez
Added:
3 years ago
Heart failure (HF) is a shared chronic phase of many cardiac diseases, including ischaemic heart disease, chronic obstructive pulmonary disease and hypertension. It is characterised by structural or functional impairment of ventricular filling or ejection of blood from the heart.1–3 It is estimated that there are more than 37.7 million cases of HF globally and its prevalence is on the rise.2 HF…
View more
Author(s):
Giuseppe Rosano
,
David Quek
,
Felipe Martínez
Added:
3 years ago
Overview
Cardiovascular (CV) disease remainsaleading cause of morbidity and mortalityworldwide with heart failure increasing in prevalence. Despite the significant advances in therapies and prevention, mortality and morbidity are still high and quality of life poor. The opportunity for CV disease prevention in patients with T2DM has recently expanded with antihyperglycemic agents demonstrating…
View more